FIELD: medicine.
SUBSTANCE: invention relates to the treatment of diabetes mellitus type I or type II and reducing the risk of nocturnal hypoglycemia. The following is proposed: a method of treating type I or type II diabetes mellitus and reducing the risk of nocturnal hypoglycemia, including administering to the patient an aqueous composition containing 270–330 IU/ml [equimolar to 270–330 IU of human insulin] insulin glargine, where the aqueous composition is administered to the patient once a day at the same time, provided that at least for two days a week the composition is administered 3 hours earlier or 3 hours later than on other days.
EFFECT: invention provides effective and safe treatment of type I or type II diabetes mellitus and reduces the risk of nocturnal hypoglycemia.
31 cl, 15 dwg, 76 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING DIABETES MELLITUS WITH LONG-ACTING INSULIN FORMULATIONS | 2014 |
|
RU2705797C2 |
| INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION | 2014 |
|
RU2684398C2 |
| LIXISENATIDE AS ADD-ON THERAPY TO BASAL INSULIN IN TYPE 2 DIABETES | 2012 |
|
RU2606154C2 |
| PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH DIABETES TYPE 2 | 2012 |
|
RU2583134C2 |
| PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2012 |
|
RU2572703C2 |
| PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2012 |
|
RU2650616C2 |
| PHARMACEUTICAL COMBINATION FOR USE FOR INDUCING WEIGHT LOSS IN SUBJECTS WITH TYPE 2 DIABETES OR/AND FOR PREVENTING WEIGHT GAIN IN SUBJECTS WITH TYPE 2 DIABETES | 2012 |
|
RU2761624C2 |
| APPLICATION OF AVE0010 FOR PRODUCTION OF MEDICATION FOR TREATMENT OF TYPE 2 DIABETES MELLITUS | 2010 |
|
RU2546520C2 |
| COMPOSITIONS OF LONG-ACTING INSULIN | 2011 |
|
RU2564104C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
